S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:ACCD

Accolade (ACCD) Stock Forecast, Price & News

$10.76
-0.14 (-1.28%)
(As of 09/22/2023 ET)
Compare
Today's Range
$10.74
$11.05
50-Day Range
$10.76
$15.02
52-Week Range
$6.83
$17.00
Volume
640,779 shs
Average Volume
625,056 shs
Market Capitalization
$813.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.59

Accolade MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
44.9% Upside
$15.59 Price Target
Short Interest
Healthy
4.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.27mentions of Accolade in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$103,506 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.69) to ($1.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Business Services Sector

57th out of 307 stocks

Business Services, Not Elsewhere Classified Industry

21st out of 85 stocks


ACCD stock logo

About Accolade (NASDAQ:ACCD) Stock

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

ACCD Price History

ACCD Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Accolade (NASDAQ: ACCD)
DOD Consultant's big 2024 prediction looks to be coming true
Earlier this year, a Department of Defense (DOD) consultant went public with a big prediction…About how a surprising 2024 event would dramatically affect you and your money. The most recent figures (published June 9th 2023) indicate he’s very likely to be right. Get the facts—learn how to prepare. Full analysis available free of charge here…
Accolade To Present at Upcoming Investor Conferences
The Latest Analyst Ratings for Accolade
Truist Financial Sticks to Its Buy Rating for Accolade (ACCD)
Why Accolade Stock Popped by Almost 7% Today
SVB Securities Reaffirms Their Hold Rating on Accolade (ACCD)
Accolade Rises as Losses Narrow in Q1
See More Headlines
Receive ACCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter.

ACCD Company Calendar

Last Earnings
6/29/2023
Today
9/22/2023
Next Earnings (Confirmed)
10/04/2023
Fiscal Year End
2/29/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:ACCD
Fax
N/A
Employees
2,370
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.59
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+43.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

Net Income
$-459,650,000.00
Pretax Margin
-41.76%

Debt

Sales & Book Value

Annual Sales
$363.14 million
Book Value
$6.51 per share

Miscellaneous

Free Float
69,354,000
Market Cap
$821.34 million
Optionable
Not Optionable
Beta
1.74
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Rajeev Singh (Age 55)
    Chairman & CEO
    Comp: $778.5k
  • Mr. Robert Cavanaugh (Age 54)
    Pres
    Comp: $582.63k
  • Mr. Stephen H. Barnes CPA (Age 51)
    CFO & Treasurer
    Comp: $557.5k
  • Ms. Kristen Bruzek
    Sr. VP of Operations
  • Mr. Colin McHugh (Age 44)
    Chief Accounting Officer
  • Mr. Todd Friedman
    Sr. VP of Investor Relations
  • Mr. Richard Eskew (Age 48)
    Exec. VP, Gen. Counsel, CCO & Sec.
  • Ms. Jennifer Hanson
    Exec. VP & Chief Human Resource Officer
  • Mr. Drew Garner
    Exec. VP of Engineering
  • Dr. Shantanu Nundy M.B.A.
    M.D., Exec. VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory Board













ACCD Stock - Frequently Asked Questions

Should I buy or sell Accolade stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings
or view top-rated stocks.

What is Accolade's stock price forecast for 2023?

15 Wall Street analysts have issued 12-month price targets for Accolade's shares. Their ACCD share price forecasts range from $13.00 to $19.00. On average, they predict the company's share price to reach $15.59 in the next year. This suggests a possible upside of 43.6% from the stock's current price.
View analysts price targets for ACCD
or view top-rated stocks among Wall Street analysts.

How have ACCD shares performed in 2023?

Accolade's stock was trading at $7.79 at the beginning of the year. Since then, ACCD stock has increased by 39.4% and is now trading at $10.86.
View the best growth stocks for 2023 here
.

When is Accolade's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023.
View our ACCD earnings forecast
.

How can I listen to Accolade's earnings call?

Accolade will be holding an earnings conference call on Wednesday, October 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Accolade's earnings last quarter?

Accolade, Inc. (NASDAQ:ACCD) posted its quarterly earnings results on Thursday, June, 29th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.10. The company had revenue of $93.20 million for the quarter, compared to analysts' expectations of $90.82 million. Accolade had a negative trailing twelve-month return on equity of 32.34% and a negative net margin of 41.86%. Accolade's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the business earned ($0.62) earnings per share.

What guidance has Accolade issued on next quarter's earnings?

Accolade issued an update on its second quarter earnings guidance on Wednesday, July, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $93.00 million-$95.00 million, compared to the consensus revenue estimate of $93.22 million.

What is Rajeev Singh's approval rating as Accolade's CEO?

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Accolade own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

When did Accolade IPO?

(ACCD) raised $176 million in an initial public offering (IPO) on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

What is Accolade's stock symbol?

Accolade trades on the NASDAQ under the ticker symbol "ACCD."

Who are Accolade's major shareholders?

Accolade's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (8.72%), Brown Advisory Inc. (8.06%), ARK Investment Management LLC (7.52%), Bellevue Group AG (5.98%), Rock Springs Capital Management LP (3.73%) and Dimensional Fund Advisors LP (2.05%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff.
View institutional ownership trends
.

How do I buy shares of Accolade?

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accolade's stock price today?

One share of ACCD stock can currently be purchased for approximately $10.86.

How much money does Accolade make?

Accolade (NASDAQ:ACCD) has a market capitalization of $821.34 million and generates $363.14 million in revenue each year. The company earns $-459,650,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

How many employees does Accolade have?

The company employs 2,370 workers across the globe.

How can I contact Accolade?

Accolade's mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The official website for the company is accolade.com. The company can be reached via phone at 206-926-8100 or via email at ir@accolade.com.

This page (NASDAQ:ACCD) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -